Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
March 03, 2023 09:00 ET
|
Ractigen Therapeutics
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RAG-17, a novel siRNA...
Muscular Dystrophy Association Announces Five Recipient Organizations of Advocacy Collaboration Grants
February 16, 2023 09:00 ET
|
Muscular Dystrophy Association
New York, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the five organizations receiving $109,065 in grant funding. The grants will promote and...
Muscular Dystrophy Association and Buffalo Bills Running Back Nyheim Hines Launch Nation's Largest St. Patrick’s Day Fundraising Campaign
February 15, 2023 09:00 ET
|
Muscular Dystrophy Association
New York, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched the nation's largest St. Patrick's Day fundraising campaign, MDA Shamrocks. Thousands of...
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
February 13, 2023 07:00 ET
|
Clene Inc.
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effectMRI results...
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
February 08, 2023 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the...
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
February 07, 2023 07:00 ET
|
AC Immune SA
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer...
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
January 31, 2023 07:05 ET
|
uniQure Inc.
~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS...
Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS
January 17, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company...
FDA’s Peter Marks, M.D., Ph.D. to deliver Keynote Address at 2023 Muscular Dystrophy Association Clinical & Scientific Conference
January 10, 2023 06:00 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Peter Marks, M.D., Ph.D. as the Keynote Speaker at the MDA 2023 Clinical & Scientific...
Muscular Dystrophy Association Elects Governor Brad Henry as Chairman and Christopher Rosa, Ph.D. as Vice Chairman of the Board of Directors
January 09, 2023 09:20 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the election of new Board of Directors leadership. Governor Brad Henry will now serve as...